Coronado Biosciences (NASDAQ: CNDO) was featured today in an article and video presentation at The Wall Street Journal titled:
Coronado is engaged in the development of novel immunotherapy biologic agents. The Company’s two principal pharmaceutical product candidates in clinical development are:
- TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis and multiple sclerosis; and
- CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors.
The WSJ article featured Coronado's work with TSO on Crohn's disease:
"While many diseases have diminished thanks to improved hygiene and medicine, people aren't exposed to bacteria that helped regulate the immune system, the theory goes. This lack of exposure may, in part, be responsible for the increase in diseases in which the body's immune system goes awry.
Based on this hygiene hypothesis, researchers at the University of Iowa wanted to find a safe parasite—one that wasn't known to cause infection or illness in humans—for therapeutic purposes. This type of treatment is known as helminthic treatment, or more specifically TSO, from the Latin name for whipworm eggs: Trichuris Suis Ova.
"It looks like the helminth [the parasite] rebalances the immune system," says Bobby Sandage, chief executive of Burlington, Mass.-based Coronado Biosciences, which is finishing up an early-stage clinical trial of whipworm to treat Crohn's disease. A Phase 2 trial is planned for this year."
Dr Robert Summers helped run the trials for Coronado Biosciences, and he is a Professor in Gastroenterology and Hepatology at the University of Iowa. According to the Wall Street Journal article there is progress in other areas too:
Multiple Sclerosis - "Another area of interest for TSO researchers is in multiple sclerosis, with two small studies published last year. One of these, published in the Multiple Sclerosis Journal, showed brain lesions decreased in four of five patients three months into treatment, and rebounded two months after it ended."
Autism - "Eric Hollander, Director of the Autism and Obsessive-Compulsive Spectrum Program at Montefiore Medical Center and Albert Einstein School of Medicine in the Bronx, N.Y., expects to begin recruiting for a human trial in adults with autism by the end of March. "People are just beginning to think about modifying the immune inflammatory response to see if it has some sort of effect on behavioral symptoms," says Dr. Hollander."
The Wall Street Journal also mentions these clinical trials using whipworm therapy have been run or are planned for the following conditions:
- Ulcerative colitis
- Rheumatoid arthritis
- Psoriatic arthritis
- Tree nut allergy
- Seasonal allergy (hay fever)
See the full article @ The Wall Street Journal
For more information please see www.CoronadoBiosciences.com.